Kamran Ahmed Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kamran Ahmed Khan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Jawaid Akbar Sial
National Institute of Cardiovascular Diseases (NICVD), Department of Adult Cardiology, Karachi, Pakistan
3 shared publicationsJehangir Ali Shah
Department of Adult Cardiology & Neurology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
3 shared publicationsMusa Karim
National Institute of Cardiovascular Diseases (NICVD), Department of Adult Cardiology, Karachi, Pakistan
3 shared publicationsTahir Saghir
National Institute of Cardiovascular Diseases (NICVD), Department of Adult Cardiology, Karachi, Pakistan
3 shared publicationsAbdul Samad Achakzai
National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
2 shared publicationsAli Ammar
Department of Adult Cardiology & Neurology, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
2 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (1) , 139-146
Significance of On-admission Impaired Estimated Glomerular Filtration Rate for the Assessment of Immediate Outcomes after Percutaneous Coronary Intervention
Objectives: Impaired baseline estimated glomerular filtration rate (eGFR) has been associated with a heightened risk of major adverse clinical events (MACE) following percutaneous coronary intervention (PCI). Early recognition of renal dysfunction on admission can help optimize clinical decision-making and improve post-PCI outcomes. This study aimed to evaluate the prognostic significance of baseline eGFR among patients with acute myocardial infarction (AMI) and its impact on immediate in-hospital outcomes after PCI. Methodology: We enrolled adult AMI patients undergoing PCI and calculated their baseline eGFR (ml/min/1.73 m²). In-hospital MACE was recorded for all patients. Participants were stratified into three groups based on eGFR values: ≥60, 45–59, and <45 ml/min/1.73 m². Results: Among 296 patients (mean age: 56.8 ± 10.8 years; 87.5% male), eGFR distribution was as follows: ≥60 in 75.3%, 45–59 in 12.8%, and <45 in 11.8%. Overall, MACE occurred in 5.7% (17 patients). The incidence of MACE was significantly higher in patients with reduced eGFR (p=0.005), observed in 3.6% of patients with eGFR ≥ 60, 7.9% with eGFR 45–59, and 17.1% with eGFR <45. In multivariable analysis, Killip class III or IV and final TIMI (thrombolysis in myocardial infarction) flow < III were identified as independent predictors of in-hospital MACE (adjusted odds ratios [ORs]: 3.81 [95% confidence interval (CI): 1.01–14.36] and 7.17 [95% CI: 2.08–24.68], respectively), while eGFR did not reach statistical significance. Conclusion: Reduced baseline eGFR was associated with a higher incidence of in-hospital MACE following PCI in AMI patients. However, after adjusting for confounders, Killip class III or IV and suboptimal final TIMI flow were more robust independent predictors of immediate adverse outcomes. Methodology: We enrolled adult AMI patients undergoing PCI and calculated their baseline eGFR (ml/min/1.73 m²). In-hospital MACE was recorded for all patients. Participants were stratified into three groups based on eGFR values: ≥60, 45–59, and <45 ml/min/1.73 m². Results: Among 296 patients (mean age: 56.8 ± 10.8 years; 87.5% male), eGFR distribution was as follows: ≥60 in 75.3%, 45–59 in 12.8%, and <45 in 11.8%. Overall, MACE occurred in 5.7% (17 patients). The incidence of MACE was significantly higher in patients with reduced eGFR (p=0.005), observed in 3.6% of patients with eGFR ≥ 60, 7.9% with eGFR 45–59, and 17.1% with eGFR <45. In multivariable analysis, Killip class III or IV and final TIMI (thrombolysis in myocardial infarction) flow < III were identified as independent predictors of in-hospital MACE (adjusted odds ratios [ORs]: 3.81 [95% confidence interval (CI): 1.01–14.36] and 7.17 [95% CI: 2.08–24.68], respectively), while eGFR did not reach statistical significance. Conclusion: Reduced baseline eGFR was associated with a higher incidence of in-hospital MACE following PCI in AMI patients. However, after adjusting for confounders, Killip class III or IV and suboptimal final TIMI flow were more robust independent predictors of immediate adverse outcomes.
- 28 February 2026
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 59 (1) , 139-146
Open AccessSignificance of On-admission Impaired Estimated Glomerular Filtration Rate for the Assessment of Immediate Outcomes after Percutaneous Coronary Intervention
Objectives: Impaired baseline estimated glomerular filtration rate (eGFR) has been associated with a heightened risk of major adverse clinical events (MACE) following percutaneous coronary intervention (PCI). Early recognition of renal dysfunction on admission can help optimize clinical decision-making and improve post-PCI outcomes. This study aimed to evaluate the prognostic significance of baseline eGFR among patients with acute myocardial infarction (AMI) and its impact on immediate in-hospital outcomes after PCI. Methodology: We enrolled adult AMI patients undergoing PCI and calculated their baseline eGFR (ml/min/1.73 m²). In-hospital MACE was recorded for all patients. Participants were stratified into three groups based on eGFR values: ≥60, 45–59, and <45 ml/min/1.73 m². Results: Among 296 patients (mean age: 56.8 ± 10.8 years; 87.5% male), eGFR distribution was as follows: ≥60 in 75.3%, 45–59 in 12.8%, and <45 in 11.8%. Overall, MACE occurred in 5.7% (17 patients). The incidence of MACE was significantly higher in patients with reduced eGFR (p=0.005), observed in 3.6% of patients with eGFR ≥ 60, 7.9% with eGFR 45–59, and 17.1% with eGFR <45. In multivariable analysis, Killip class III or IV and final TIMI (thrombolysis in myocardial infarction) flow < III were identified as independent predictors of in-hospital MACE (adjusted odds ratios [ORs]: 3.81 [95% confidence interval (CI): 1.01–14.36] and 7.17 [95% CI: 2.08–24.68], respectively), while eGFR did not reach statistical significance. Conclusion: Reduced baseline eGFR was associated with a higher incidence of in-hospital MACE following PCI in AMI patients. However, after adjusting for confounders, Killip class III or IV and suboptimal final TIMI flow were more robust independent predictors of immediate adverse outcomes. Methodology: We enrolled adult AMI patients undergoing PCI and calculated their baseline eGFR (ml/min/1.73 m²). In-hospital MACE was recorded for all patients. Participants were stratified into three groups based on eGFR values: ≥60, 45–59, and <45 ml/min/1.73 m². Results: Among 296 patients (mean age: 56.8 ± 10.8 years; 87.5% male), eGFR distribution was as follows: ≥60 in 75.3%, 45–59 in 12.8%, and <45 in 11.8%. Overall, MACE occurred in 5.7% (17 patients). The incidence of MACE was significantly higher in patients with reduced eGFR (p=0.005), observed in 3.6% of patients with eGFR ≥ 60, 7.9% with eGFR 45–59, and 17.1% with eGFR <45. In multivariable analysis, Killip class III or IV and final TIMI (thrombolysis in myocardial infarction) flow < III were identified as independent predictors of in-hospital MACE (adjusted odds ratios [ORs]: 3.81 [95% confidence interval (CI): 1.01–14.36] and 7.17 [95% CI: 2.08–24.68], respectively), while eGFR did not reach statistical significance. Conclusion: Reduced baseline eGFR was associated with a higher incidence of in-hospital MACE following PCI in AMI patients. However, after adjusting for confounders, Killip class III or IV and suboptimal final TIMI flow were more robust independent predictors of immediate adverse outcomes.
- Open Access
- 30 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (21) , 104396
Successful Retrieval of Dislodged Stent and Fractured Balloon After Entrapment in One Setting
- 30 July 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (21) , 104396
Open AccessSuccessful Retrieval of Dislodged Stent and Fractured Balloon After Entrapment in One Setting
- Open Access
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1248506
Case report: Navigating the challenges: successful mechanical thrombectomy in a case of persistent primitive hypoglossal artery
Persistent primitive hypoglossal artery (PPHA) is a highly uncommon abnormal connection between the internal carotid artery (ICA) and vertebral artery (VA), with reported incidences ranging from 0.027 to 0.26%. Attempting endovascular intervention in such cases presents a considerable challenge as it carries a higher risk of embolization and other procedure-related complications that may affect a wide area of the brain. We present a case study involving the utilization of mechanical thrombectomy (MT) to treat an ischemic stroke in the M1 segment of the middle cerebral artery (MCA) despite the presence of PPHA. Performing mechanical thrombectomy in an anomalous vascular connection is feasible; however, it necessitates heightened vigilance, thorough knowledge of the anatomy, and utmost caution.
- 24 November 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1248506
Open AccessCase report: Navigating the challenges: successful mechanical thrombectomy in a case of persistent primitive hypoglossal artery
Persistent primitive hypoglossal artery (PPHA) is a highly uncommon abnormal connection between the internal carotid artery (ICA) and vertebral artery (VA), with reported incidences ranging from 0.027 to 0.26%. Attempting endovascular intervention in such cases presents a considerable challenge as it carries a higher risk of embolization and other procedure-related complications that may affect a wide area of the brain. We present a case study involving the utilization of mechanical thrombectomy (MT) to treat an ischemic stroke in the M1 segment of the middle cerebral artery (MCA) despite the presence of PPHA. Performing mechanical thrombectomy in an anomalous vascular connection is feasible; however, it necessitates heightened vigilance, thorough knowledge of the anatomy, and utmost caution.
- Open Access
- 16 March 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 171, 32-39
Development and Validation of a Novel Risk Stratification Model for Slow-Flow/No-Reflow During Primary Percutaneous Coronary Intervention (the RK-SF/NR Score)
- 16 March 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 171, 32-39
Open AccessDevelopment and Validation of a Novel Risk Stratification Model for Slow-Flow/No-Reflow During Primary Percutaneous Coronary Intervention (the RK-SF/NR Score)
- Open Access
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (2) , 163-171
Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial)
Background: Intracoronary epinephrine has been effectively used in treating refractory no-reflow, but there is a dearth of data on its use as a first-line drug in normotensive patients in comparison to the widely used adenosine. Methods: In this open-labeled randomized clinical trial, 201 patients with no-reflow were randomized 1:1 into intracoronary epinephrine as the treatment group and intracoronary adenosine as the control group and followed for 1 month. The primary end points were improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow, frame counts, and myocardial blush. Secondary end points were in-hospital and short-term mortality and major adverse cardiac events. Results: In all, 101 patients received intracoronary epinephrine and 100 patients received adenosine. Epinephrine was generally well tolerated with no immediate table death or ventricular fibrillation. No-reflow was more effectively improved with epinephrine with final TIMI III flow (90.1% versus 78%, P =0.019) and final corrected TIMI frame count (24±8.43 versus 26.63±9.22, P =0.036). However, no significant difference was observed in final grade III myocardial blush (55.4% versus 45%, P =0.139), mean reduction of corrected TIMI frame count (−25.71±11.79 versus −26.08±11.71, P =0.825), in-hospital and short-term mortality, and major adverse cardiac events. Conclusions: Epinephrine is relatively safe to use in no-reflow in normotensive patients. A significantly higher frequency of post-treatment TIMI III flow grade and lower final corrected TIMI frame count with relatively better achievement of myocardial blush grade III translate into it displaying relatively better efficacy than adenosine. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04699110.
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 15 (2) , 163-171
Open AccessComparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial)
Background: Intracoronary epinephrine has been effectively used in treating refractory no-reflow, but there is a dearth of data on its use as a first-line drug in normotensive patients in comparison to the widely used adenosine. Methods: In this open-labeled randomized clinical trial, 201 patients with no-reflow were randomized 1:1 into intracoronary epinephrine as the treatment group and intracoronary adenosine as the control group and followed for 1 month. The primary end points were improvement in coronary flow, as assessed by TIMI (Thrombolysis in Myocardial Infarction) flow, frame counts, and myocardial blush. Secondary end points were in-hospital and short-term mortality and major adverse cardiac events. Results: In all, 101 patients received intracoronary epinephrine and 100 patients received adenosine. Epinephrine was generally well tolerated with no immediate table death or ventricular fibrillation. No-reflow was more effectively improved with epinephrine with final TIMI III flow (90.1% versus 78%, P =0.019) and final corrected TIMI frame count (24±8.43 versus 26.63±9.22, P =0.036). However, no significant difference was observed in final grade III myocardial blush (55.4% versus 45%, P =0.139), mean reduction of corrected TIMI frame count (−25.71±11.79 versus −26.08±11.71, P =0.825), in-hospital and short-term mortality, and major adverse cardiac events. Conclusions: Epinephrine is relatively safe to use in no-reflow in normotensive patients. A significantly higher frequency of post-treatment TIMI III flow grade and lower final corrected TIMI frame count with relatively better achievement of myocardial blush grade III translate into it displaying relatively better efficacy than adenosine. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04699110.
- Open Access
- 1 January 2022
- Published by SAGE Publications in Sage Open Medicine
- Vol. 10
Comparison of angiographic results and clinical outcomes of no-reflow after stenting in left anterior descending (LAD) versus non-LAD culprit STEMI
Objectives: No-reflow is a complication that frequently occurs after stenting during primary percutaneous coronary intervention. In this study, we focused on angiographic results and clinical outcomes after no-reflow in the left anterior descending (LAD) artery versus non–left anterior descending artery ST-elevation myocardial infarction (STEMI). Methods: In this prospective study, a total of 201 patients who had developed no-reflow during primary percutaneous coronary intervention were enrolled. The patients were divided into left anterior descending artery culprit and non-left anterior descending artery culprit groups. The primary endpoints were final thrombolysis in myocardial infarction flow, corrected thrombolysis in myocardial infarction frame count and final myocardial blush grade. Secondary endpoints were major adverse cardiovascular events in-hospital and at 1 month. Results: Out of the 201 patients, 60.19% had culprit left anterior descending artery. Pulse rate, baseline systolic and diastolic blood pressure, single-vessel disease, left ventricular ejection fraction 40% were significantly greater in the non–left anterior descending artery group. However, for both in-hospital and at 30 days, overall major adverse cardiovascular event was similar in the two groups. The demographics, clinical and medication profiles and the routes used to treat no-reflow were all comparable in both groups. Conclusions: No-reflow in left anterior descending artery ST-elevation myocardial infarction is associated with lower final thrombolysis in myocardial infarction III flow, higher thrombolysis in myocardial infarction frame count and relatively lower Grade III myocardial blush than non-left anterior descending artery ST-elevation myocardial infarction with subsequent lower left ventricular ejection fraction and a higher frequency of in-hospital heart failure and hospitalisation due to heart failure.
- 1 January 2022
- Published by SAGE Publications in Sage Open Medicine
- Vol. 10
Open AccessComparison of angiographic results and clinical outcomes of no-reflow after stenting in left anterior descending (LAD) versus non-LAD culprit STEMI
Objectives: No-reflow is a complication that frequently occurs after stenting during primary percutaneous coronary intervention. In this study, we focused on angiographic results and clinical outcomes after no-reflow in the left anterior descending (LAD) artery versus non–left anterior descending artery ST-elevation myocardial infarction (STEMI). Methods: In this prospective study, a total of 201 patients who had developed no-reflow during primary percutaneous coronary intervention were enrolled. The patients were divided into left anterior descending artery culprit and non-left anterior descending artery culprit groups. The primary endpoints were final thrombolysis in myocardial infarction flow, corrected thrombolysis in myocardial infarction frame count and final myocardial blush grade. Secondary endpoints were major adverse cardiovascular events in-hospital and at 1 month. Results: Out of the 201 patients, 60.19% had culprit left anterior descending artery. Pulse rate, baseline systolic and diastolic blood pressure, single-vessel disease, left ventricular ejection fraction 40% were significantly greater in the non–left anterior descending artery group. However, for both in-hospital and at 30 days, overall major adverse cardiovascular event was similar in the two groups. The demographics, clinical and medication profiles and the routes used to treat no-reflow were all comparable in both groups. Conclusions: No-reflow in left anterior descending artery ST-elevation myocardial infarction is associated with lower final thrombolysis in myocardial infarction III flow, higher thrombolysis in myocardial infarction frame count and relatively lower Grade III myocardial blush than non-left anterior descending artery ST-elevation myocardial infarction with subsequent lower left ventricular ejection fraction and a higher frequency of in-hospital heart failure and hospitalisation due to heart failure.
- 26 May 2021
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 54 (1) , 97-106
TERRITORIAL IMPACT ON CLINICAL OUTCOMES IN YOUNG POPULATION WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Objective: ST-segment elevation myocardial infarction (STEMI) at younger age though infrequent but very crucial entity, but there is dearth of available data, however, a rising trend has noticed recently in Asian countries. The aim was to see the territorial and clinical profile influence on overall outcomes of young individuals (≤35 years) with STEMI. Methodology: Patients with STEMI having age of ≤35 years during August 2020 to December 2020 were recruited and divided into left anterior descending artery (LAD)-culprit and non-LAD-culprit STEMI groups in this prospective observational study. Territorial angiographic and clinical characteristics were compared. Results: 1435 STEMI patients underwent coronary angiogram, 5.3% (94) were ≤35 years of age. LAD was culprit in 74.4% of STEMI mainly as a single vessel disease (SVD) involving the proximal segment as major territorial angiographic finding while 25.5% were non-LAD-culprit STEMI. Obesity, smoking, smokeless tobacco use especially gutka, were frequent in LAD-culprit group. In-hospital and at 3 months mortality was 2.1% (2) and 7.1% (5) respectively, all related to LAD territory. Rate of safe discharges and back to routine was 97.2% vs.100% and 70% vs.79.1% (72), respectively were comparable in both groups. Conclusion: LAD predominantly its proximal segment is the commonest culprit territory in patients with STEMI in youth with significant association to obesity, smoking and smokeless tobacco use especially gutka. LAD-culprit STEMI is the major territorial determinant for mortality and heart failure, however, overall clinical outcomes were reasonably good and comparable with non-LAD-culprit STEMI considering alive discharges and back to routine life.
- 26 May 2021
- Published by Pakistan Cardiac Society in Pakistan Heart Journal
- Vol. 54 (1) , 97-106
TERRITORIAL IMPACT ON CLINICAL OUTCOMES IN YOUNG POPULATION WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION
Objective: ST-segment elevation myocardial infarction (STEMI) at younger age though infrequent but very crucial entity, but there is dearth of available data, however, a rising trend has noticed recently in Asian countries. The aim was to see the territorial and clinical profile influence on overall outcomes of young individuals (≤35 years) with STEMI. Methodology: Patients with STEMI having age of ≤35 years during August 2020 to December 2020 were recruited and divided into left anterior descending artery (LAD)-culprit and non-LAD-culprit STEMI groups in this prospective observational study. Territorial angiographic and clinical characteristics were compared. Results: 1435 STEMI patients underwent coronary angiogram, 5.3% (94) were ≤35 years of age. LAD was culprit in 74.4% of STEMI mainly as a single vessel disease (SVD) involving the proximal segment as major territorial angiographic finding while 25.5% were non-LAD-culprit STEMI. Obesity, smoking, smokeless tobacco use especially gutka, were frequent in LAD-culprit group. In-hospital and at 3 months mortality was 2.1% (2) and 7.1% (5) respectively, all related to LAD territory. Rate of safe discharges and back to routine was 97.2% vs.100% and 70% vs.79.1% (72), respectively were comparable in both groups. Conclusion: LAD predominantly its proximal segment is the commonest culprit territory in patients with STEMI in youth with significant association to obesity, smoking and smokeless tobacco use especially gutka. LAD-culprit STEMI is the major territorial determinant for mortality and heart failure, however, overall clinical outcomes were reasonably good and comparable with non-LAD-culprit STEMI considering alive discharges and back to routine life.